We present a case of metastatic castration-resistant prostate cancer (mCRPC) who developed pancytopenia following the Ac-225-PSMA-617 treatment period, a bone marrow biopsy confirmed SMF and remained uncorrected after multiple component transfusions and symptomatic supportive therapy. This evidence concerns the gene FOLH1 and Pancytopenia.